Skip to main content
RIBOMIC Inc. logo

RIBOMIC Inc. — Investor Relations & Filings

Ticker · 4591 ISIN · JP3974850004 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2023-02-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4591

About RIBOMIC Inc.

https://www.ribomic.com/eng/

RIBOMIC Inc. is a biopharmaceutical company engaged in the discovery and development of novel molecular-targeted therapeutics using its proprietary RNA aptamer technology. The company's core drug discovery platform, the RiboART System (Ribomic Aptamer Refined Therapeutics System), enables the creation of aptamers that bind to target molecules with high affinity and specificity. RIBOMIC's development pipeline focuses on addressing significant unmet medical needs in various therapeutic areas. Key clinical programs include potential treatments for ophthalmic conditions, such as wet age-related macular degeneration, and rare genetic disorders like achondroplasia.

Recent filings

Filing Released Lang Actions
四半期報告書－第20期第3四半期(2022/10/01－2022/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the 20th fiscal period (2022-10-01 to 2022-12-31) for RIBOMIC Inc. It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-02-13 Japanese
四半期報告書－第20期第2四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report
2022-11-14 Japanese
確認書
Regulatory Filings
2022-11-14 Japanese
四半期報告書－第20期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the first quarter of the 20th fiscal period (April 1, 2022, to June 30, 2022) for RIBOMIC Inc. It contains detailed financial statements, management analysis of financial conditions, and business results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-08-10 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Quarterly Report (Dai-ichi shihanki hokokusho). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the report's contents. Given the specific nature of this regulatory confirmation filing, it falls under the RNS category as a general regulatory filing.
2022-08-10 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 2022
2022-06-29 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.